Drug intelligence / Profile preview

IgG-RFB4-SMPT-dgA

Development stage: Phase 1
Lead developer: National Cancer Institute
Modality: Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IgG-RFB4-SMPT-dgA is an immunotoxin consisting of deglycosylated ricin A chain (dgA) coupled to the monoclonal antihuman CD22 antibody RFB4 via a sterically hindered disulfide linker (SMPT). It selectively targets CD22-positive B-cell malignancies, where the ricin A chain component inhibits protein synthesis in target cells, leading to cell death. This agent has demonstrated antitumor activity in clinical trials for B-cell lymphomas.

Other names: RFB4-SMPT-dgARFB-4-SMPT-dgARFB 4-SMPT-dgARFB4-dgARFB-4-dgARFB 4-dgA

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on IgG-RFB4-SMPT-dgA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgG-RFB4-SMPT-dgA.

Explore the full profile